Evidence map›Paper›PMID 33004476›Full record

ArticleCancer discovery2020

Immunosurveillance and Regression in the Context of Squamous Pulmonary Premalignancy.

Kostyantyn Krysan, Linh M Tran, Steven M Dubinett

Open access · greenAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Immune evasion in HPVProceedings of the National Academy of Sciences of the United States of America · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kostyantyn KrysanJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.ORCID https://orcid.org/0000-0003-0250-1346
Linh M TranJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.ORCID https://orcid.org/0000-0001-8597-643X
Steven M DubinettJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California. sdubinett@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung CancerU01CA196408 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ABERLE, DENISE R., DUBINETT, STEVEN M. · 2015 to 2021
$7.1M
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary PremalignancyU2CCA233238 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI DUBINETT, STEVEN M., SPIRA, AVRUM E · 2018 to 2021
$7.0M
The Boston University-UCLA Lung Cancer Biomarker Development LabU01CA214182 · NCI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ABERLE, DENISE R., DUBINETT, STEVEN M. · 2016 to 2021
$3.1M
NCATS NIH HHS UL1 TR001881NCI NIH HHS U01 CA196408NCI NIH HHS U01 CA214182NCI NIH HHS U2C CA233238
6 · The paper itself

Abstract

In this issue of

Indexed as

Carcinoma, Squamous CellLung NeoplasmsPrecancerous ConditionsEpithelial CellsHumansMonitoring, Immunologic

Identifiers

PMID33004476
PMCPMC8396076
OpenAlexW3091421496

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.